NCT00526617CompletedPhase 1
A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)
AbbVie0 sites41 target enrollmentStarted: August 2007Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 41
- Primary Endpoint
- Maximum Tolerated Dose
Study Overview
Brief Summary
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).
Detailed Description
A Phase 1, multicenter, dose-escalation study evaluating the safety and tolerability of the PARP inhibitor ABT-888 in combination with Temozolomide (TMZ) in subjects with non-hematologic malignancies (NHM), including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Dose escalation and expanded safety cohorts
- •Evaluable disease, histologically confirmed malignancy (metastatic or unresectable) and standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective
- •ECOG Performance Score less than or equal to 2
- •Adequate hematologic, renal and hepatic function
- •Normal sodium, calcium and magnesium levels
- •Voluntarily signed informed consent
- •Expanded Safety Cohorts Only
- •Population:
- •Metastatic melanoma (MM)
- •Hepatocellular carcinoma (HCC) Child Pugh Category A and B classification only
- •BRCA deficient tumor status*: advanced breast cancer (with soft tissue disease), or advanced ovarian cancer, or advanced primary peritoneal cancer, or advanced fallopian tube cancer*
- •*Patients must have histologically or cytologically confirmed solid tumors with a positive genetic test result documenting BRCA 1 or BRCA 2 mutation status, to be considered eligible.
- •Serial tumor biopsies: Required for all subjects enrolled in one of the Expanded Low Dose Safety Cohorts.
Exclusion Criteria
- •Dose Escalation and Expanded Safety Cohorts
- •Known central nervous system (CNS) metastases or CNS primary cancer.
- •Previous or current malignancies at other sites, except: adequately treated in situ carcinoma of cervix uteri; basal/squamous cell carcinoma of skin; previous malignancy considered cured.
- •Previous history or current seizure disorder.
- •Clinically significant and uncontrolled major medical condition(s) or any medical condition that places the subject at an unacceptably high risk for toxicities.
- •Transplant recipients and patients receiving combination anti-retroviral therapy for HIV due to the use of immunosuppressant therapies.
- •Lactating or pregnant female.
- •Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy will not be allowed within either 4 weeks, or 5 half lives of a targeted therapy prior to study drug administration (Study Day 1).
- •Prior therapy with regimens containing dacarbazine (DTIC) or TMZ is not permitted.
- •Anti-cancer therapy is not permitted during the treatment portion of the study.
- •Hormone therapy, bisphosphonates or LHRH-agonists for prostate cancer are permitted prior to and during the study.
- •Significant adverse event or toxicity due to previous anti-cancer treatment that has not recovered to within one grade level (not to exceed Grade 2) of baseline.
- •Expanded Safety Cohorts Only:
- •MM Only: Prior treatment with DNA damaging agents or cytotoxic chemotherapy including carboplatin, cisplatin, fotemustine, paclitaxel, vincristine, TMZ and DTIC.
- •Prior therapy with biologic agents (including IL-2, interferon, bevacizumab, vaccines and immunostimulants) and signal transduction inhibitors (including sorafenib, erlotinib, sutent and elesclomol) are allowed.
- •Lower Dose Expanded Safety Cohorts Only
- •Anti-coagulant restrictions for subjects that have tumor biopsies.
Arms & Interventions
Open Label
Experimental
Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
Intervention: ABT-888 (Drug)
Open Label
Experimental
Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
Intervention: Temozolomide (Drug)
Outcomes
Primary Outcomes
Maximum Tolerated Dose
Time Frame: Duration of Study
Safety and Tolerability
Time Frame: Duration of Study
Pharmacokinetic Profile
Time Frame: Duration of Study
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 1
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesBrain DiseasesBrain NeoplasmsCentral Nervous System DiseasesNeoplasm MetastasisNervous System NeoplasmsNCT00649207AbbVie (prior sponsor, Abbott)80
Completed
Phase 1
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsAdult Solid NeoplasmBRCA1 Mutation CarrierBRCA2 Mutation CarrierNCT01154426National Cancer Institute (NCI)31
Completed
Phase 1
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2AAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAdult Pure Erythroid LeukemiaChronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 PositiveDe Novo Myelodysplastic SyndromeHematopoietic and Lymphoid Cell NeoplasmRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaPolycythemia VeraEssential ThrombocythemiaMyelodysplastic SyndromeNCT00588991National Cancer Institute (NCI)12
Completed
Phase 1
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsChildhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Spinal Cord NeoplasmRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaNCT00946335National Cancer Institute (NCI)31
Completed
Phase 1
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsAdult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeMale Breast CarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerTriple-Negative Breast CarcinomaNCT01281150National Cancer Institute (NCI)22